Sigrid Stroobants
Overview
Explore the profile of Sigrid Stroobants including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
5854
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leupe H, Pauwels E, Vandamme T, Van den Broeck B, Lybaert W, Dekervel J, et al.
J Neuroendocrinol
. 2024 Jun;
36(8):e13420.
PMID: 38837825
[F]AlF-NOTA-octreotide ([F]AlF-OC) is a promising alternative for [Ga]Ga-DOTA-somatostatin analogs (SSAs) in positron emission tomography (PET) imaging of the somatostatin receptor (SSTR). Our aim is to assess changes in TNM staging...
2.
Robeyns R, Sisto A, Iturrospe E, Da Silva K, van de Lavoir M, Timmerman V, et al.
Metabolites
. 2024 May;
14(5).
PMID: 38786725
Torin1, a selective kinase inhibitor targeting the mammalian target of rapamycin (mTOR), remains widely used in autophagy research due to its potent autophagy-inducing abilities, regardless of its unspecific properties. Recognizing...
3.
Tanc M, Filippi N, Van Rymenant Y, Grintsevich S, Pintelon I, Verschuuren M, et al.
J Med Chem
. 2024 Apr;
67(9):7068-7087.
PMID: 38656144
Fibroblast activation protein (FAP) is a very reliable biomarker for tissue remodeling. FAP has so far mainly been studied in oncology, but there is growing interest in the enzyme in...
4.
Mileva M, de Vries E, Guiot T, Wimana Z, Deleu A, Schroder C, et al.
NPJ Breast Cancer
. 2024 Jan;
10(1):4.
PMID: 38184611
Efficacy of the human epidermal growth factor receptor (HER)2-targeting trastuzumab emtansine (T-DM1) in breast cancer (BC) relies on HER2 status determined by immunohistochemistry or fluorescence in-situ hybridization. Heterogeneity in HER2...
5.
Adhikari K, Dewulf J, Vangestel C, Van der Veken P, Stroobants S, Elvas F, et al.
ACS Omega
. 2023 Oct;
8(41):38252-38262.
PMID: 37867688
The pretargeted imaging strategy using inverse electron demand Diels-Alder (IEDDA) cycloaddition between a -cyclooctene (TCO) and tetrazine (Tz) has emerged and rapidly grown as a promising concept to improve radionuclide...
6.
Metelerkamp Cappenberg T, De Schepper S, Vangestel C, De Lombaerde S, Wyffels L, Van den Wyngaert T, et al.
EJNMMI Radiopharm Chem
. 2023 Aug;
8(1):20.
PMID: 37646865
Background: Imaging of cell death can provide an early indication of treatment response in cancer. [Tc]Tc-Duramycin is a small-peptide SPECT tracer that recognizes both apoptotic and necrotic cells by binding...
7.
Jackson A, Pathak R, deSouza N, Liu Y, Jacobs B, Litiere S, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509240
Tumour apparent diffusion coefficient (ADC) from diffusion-weighted magnetic resonance imaging (MRI) is a putative pharmacodynamic/response biomarker but the relationship between drug-induced effects on the ADC and on the underlying pathology...
8.
Boeckxstaens L, Pauwels E, Vandecaveye V, Deckers W, Cleeren F, Dekervel J, et al.
EJNMMI Res
. 2023 Jun;
13(1):53.
PMID: 37261615
Background: Fluorine-18-labeled SSAs have the potential to become the next-generation tracer in SSTR-imaging in neuroendocrine tumor (NET) patients given their logistical advantages over the current gold standard gallium-68-labeled SSAs. In...
9.
Dockx Y, Vangestel C, De Bruycker S, Van den Wyngaert T, Huizing M, Staelens S, et al.
Cancer Biother Radiopharm
. 2022 Dec;
38(1):51-61.
PMID: 36472460
To evaluate F-fluoro-2-deoxy-glucose (F-FDG) and F-fluorothymidine (F-FLT) as early-response biomarkers for phosphoinositide-3-kinase/Akt/mammalian-target-of-rapamycin (PI3K/Akt/mTOR) inhibition in breast cancer (BC) models. Two human epidermal growth factor receptor 2 (HER2)-positive (trastuzumab-sensitive SKBR3; trastuzumab-resistant...
10.
Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Boeckxstaens L, et al.
J Nucl Med
. 2022 Oct;
64(4):632-638.
PMID: 36265911
F-labeled somatostatin analogs (SSAs) could represent a valid alternative to the current gold standard, Ga-labeled SSAs, for somatostatin receptor imaging in patients with neuroendocrine tumors (NETs), given their logistic advantages....